Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target by Montero, Juan Carlos et al.
Expression of Erk5 in Early Stage Breast Cancer and
Association with Disease Free Survival Identifies this
Kinase as a Potential Therapeutic Target
Juan Carlos Montero
1., Alberto Ocan ˜a
2., Mar Abad
3, Marı ´a Jesu ´s Ortiz-Ruiz
1, Atanasio Pandiella
1,
Azucena Esparı ´s-Ogando
1*
1Instituto de Biologı ´a Molecular y Celular del Ca ´ncer, CSIC-Universidad de Salamanca, Salamanca, Spain, 2Oncology Service and AECC Unit, Complejo Hospitalario
Universitario de Albacete, Albacete, Spain, 3Department of Pathology, Hospital Universitario de Salamanca, Salamanca, Spain
Abstract
Background: Breast cancer is the most common neoplasia in women. Even though advances in its treatment have
improved disease outcome, some patients relapse. Therefore, attempts to better define the molecular determinants that
drive breast cancer cell proliferation may help in defining potential therapeutic targets. Mitogen-activated protein kinases
(MAPK) play important roles in tumorigenesis. One of them, Erk5, has been linked to the proliferation of breast cancer cells
in vitro. Here we have investigated the expression and prognostic value of Erk5 in human breast cancer.
Methodology/Principal Findings: Animal and cellular models were used to study Erk5 expression and function in breast
cancer. In 84 human breast tumours the expression of Erk5 was analyzed by immunohistochemistry. Active Erk5 (pErk5) was
studied by Western blotting. Correlation of Erk5 with clinicopathological parameters and with disease-free survival in early
stage breast cancer patients was analyzed. Expression of Erk5 was detected in most patients, and overexpression was found
in 20%. Active Erk5 was present in a substantial number of samples, as well as in tumours from an animal breast cancer
model. Overexpression of Erk5 was associated with a decrease in disease-free survival time, which was independent of other
clinicopathological parameters of prognosis. Transient transfection of a short hairpin RNA (shRNA) targeting Erk5, and a
stable cell line expressing a dominant negative form of Erk5 (Erk5
AEF), were used to investigate the influence of Erk5 on
drugs used in the clinic to treat breast tumours. We found that inhibition of Erk5 decreased cancer cell proliferation and also
sensitized these cells to the action of anti-HER2 therapies.
Conclusions/Significance: Overexpression of Erk5 is an independent predictor of disease-free survival in breast cancer, and
may represent a future therapeutic target.
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Introduction
Breast cancer represents the most common cancer type in
women [1,2]. Although important advances in the treatment of
this disease have improved patient survival, its disseminated
metastatic form still remains incurable. Furthermore, a number of
early stage breast cancer patients will relapse regardless of the
adjuvant treatment given. Because of this, substantial efforts have
been made to better understand the molecular bases of the disease
in order to achieve more efficient treatments. These studies led to
the identification of certain oncogenic stimuli linked to the genesis
and/or progression of breast cancer. One of these oncogenic
proteins is the transmembrane tyrosine kinase HER2 [3]. This
kinase belongs to the family of mammalian HER/ErbB receptors,
that includes the epidermal growth factor receptor (EGFR or
HER1), HER2/ErbB2, HER3/ErbB3, and HER4/ErbB4 [4].
Overexpression of HER2 occurs in 20–30% of breast cancer
tumours, and is linked to a more aggressive phenotype and a worse
prognosis [3]. The identification of HER2 as an important
oncogene in breast cancer led to the development of anti-HER2
therapies such as the monoclonal antibody trastuzumab (Hercep-
tinH) or the small tyrosine kinase inhibitor lapatinib. Treatment
with these agents has demonstrated efficacy in breast cancer
patients overexpressing HER2 [5–7].
Tumorigenic signalling from HER receptors involves the
activation of several signal transduction routes. Among the most
PLoS ONE | www.plosone.org 1 May 2009 | Volume 4 | Issue 5 | e5565important are the Mitogen-Activated Protein Kinases (MAPK)
and the Phosphatidylinositol-3-kinase (PI3K)/Akt routes [4]. Four
major MAPK routes have been described [8]. The Erk1/2
pathway is activated by growth factor receptors and transduces
proliferation signals. Another two MAPK routes, the p38 and Jun
kinase pathways, are activated by several cytokines and stress
stimuli, and have been mainly linked to the regulation of apoptotic
cell death [9]. Recently, a novel MAPK termed Erk5 has also been
involved in the control of cellular proliferation and cell death, as
well as in tumorigenesis [10]. Elegant in vivo studies using animals
in which Erk5 expression can be regulated, have demonstrated
that Erk5 is important for sustaining tumour growth, probably due
to its supportive role in vasculogenesis and blood vessel
homeostasis [11,12]. In the breast, Erk5 activation has been
linked to growth factor-induced proliferation of normal breast
epithelial cells [13] as well as breast cancer cells [13,14]. In the
latter, activation of HER receptors by the ligand Neuregulin
(NRG) provoked Erk5 activation [14]. Furthermore, restriction of
Erk5 activation by expression of a dominant negative inhibitory
form partially blocked proliferation of breast cancer cells [14].
Interestingly, in vitro studies showed that Erk5 activity is
constitutively high in breast cancer cell lines overexpressing
HER2 [14].
These precedents support a potential role of Erk5 in breast
cancer initiation/progression. We therefore decided to explore the
in vivo expression and activation status of Erk5, its potential
association to HER2 overexpression, and prognostic relevance in
breast cancer. We show that Erk5 is overexpressed in the tumours
of a number of breast cancer patients. Moreover, our findings
indicate that Erk5 overexpression is an independent prognostic
marker for disease-free survival. In addition, in vitro studies
indicated that inhibition of Erk5 sensitized cells to treatments
commonly used in the breast cancer clinic. Therefore, Erk5 may
represent a new prognostic marker in breast cancer, and could also
represent a novel therapeutic target.
Materials and Methods
Patient samples and immunohistochemistry
During the period from 1999 to 2005 a total of 84 breast
tumours were randomly obtained from the Pathology Department
of the Salamanca University Hospital (Salamanca, Spain). All
patients provided written informed consent for the collection of
samples and subsequent analysis. The procedures were approved
by the Institutional Review Board Ethics Committee on Human
Research of the Salamanca University Hospital. The clinicopath-
ological characteristics of these patients are described in Table 1.
HER2 was analyzed using the Dako Herceptest kit (DakoCy-
tomation, Carpinteria, CA). Erk5 expression was analyzed using
an affinity-purified antibody, that specifically recognizes the C-
terminus of Erk5 (residues 781–805) [14]. That this antibody
specifically detected Erk5 in immunohistochemistry was indicated
by the prevention of the Erk5 staining upon preincubation of the
antibody with the peptide against which the antibody had been
raised (data not shown, see also ref. [14]). For the clinicopatho-
logical studies, Erk5 expresion levels were scored only in the
epithelial tumoral cells. A quantitative analysis was based on the
percentage of stained cells and intensity of the staining, and was
defined as follows: 0, no appreciable staining in cells (0 to ,10%);
1, weak intensity in cells (between 10% and 30%); 2, intermediate
intensity of staining (30% to 60%); and 3, strong intensity of
staining (.60%). Normal breast stained with an intensity that
scored as 1. Tumours were considered positive (Erk5 high) when
scored 2 or 3, and negative when scored 0 or 1. HER2 gene
amplification (evaluated by FISH DAKO HER2 FISH
pharmDx
TM Kit, DakoCytomation, Glostrup, Denmark A/S)
was defined as a HER2-chromosome 17 ratio of .2.0, as required
by the guidelines.
Statistical analyses
Statistical analyses were performed using the SPSS Data
Analysis Program, version 13.0 (SPSS, Inc., Chicago, IL).
Association between two dichotomous variables was determined
using the chi-square test and two tailed Fisher’s exact test.
Spearman’s nonparametric correlation test was used to calculate
the statistical significance of continuous variables. Mann-Whitney
U test was used to compare continuous variables with dichotomic
or ordinal variables. Disease Free Survival (DFS) was calculated
from the date of diagnosis to the date of recurrence or death.
Patients who were event free at the date of last follow-up were
censored at that time. Kaplan-Meier survival analyses were carried
out for DFS. Differences in DFS according to Erk5 expression
were compared using the Log-rank test. Multivariate analysis using
the Cox proportional hazards models was performed to define
prognostic independent factors for DFS. All statistical tests were
conducted at a two-sided significance level of 0.05.
Cell culture and transfections
The cell line BT474 was cultured at 37uC in a humidified
atmosphere in the presence of 5% CO2–95% air. Cells were
grown in Dulbecco’s modified Eagle medium (DMEM) containing
a high glucose concentration (4,500 mg/liter) and antibiotics
(penicillin at 100 U/ml, streptomycin at 100 mg/ml) and supple-
mented with 10% foetal bovine serum (FBS).
Transfections of BT474 cells with pSuper or pSuper-shErk5
[15] were performed using LipofectAMINE (Invitrogen, San
Diego, CA) following the manufacturer’s instructions. BT474 cells
that express HA-Erk5
AEF have been described [14].
Cell proliferation measurements
Subconfluent monolayer cultures were trypsinized, and cells
were plated in 24-well plates at a density of 20,000 per well.
Cultures were allowed to attach overnight, and the medium was
then replaced with medium containing lapatinib 100 nM or
trastuzumab 10 nM. Cell proliferation was analyzed at 3 days by
an MTT-based assay [14]. Briefly, the medium in each well was
replaced with 250 ml of fresh medium containing MTT at 0.5 mg/
Table 1. Patient and Tumour Characteristics (n=84).
Patient age (n=81) median 58 (range 31–89)
Grade (n=77) 1–2 32
34 5
Tumour diameter (mm) (n=72) median 26.5 (range 8–75 mm)
Estrogen Receptors (n=84) Positive 52
Negative 32
Progesterone Receptors (n=84) Positive 49
Negative 35
HER2 FISH (n=84) Positive 24
Negative 60
Lymph nodes (n=77) Positive 51
Negative 26
doi:10.1371/journal.pone.0005565.t001
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MTT was then removed, 500 ml of dimethyl sulfoxide was added
to each well, and the plate was kept in agitation for 5 min in the
dark to dissolve the MTT-formazan crystals. The absorbance of
the samples was then recorded at 570 nm. Four wells were
analyzed for each condition, and wells containing medium plus
MTT but no cells were used as blanks. The results are presented as
the mean 6 the standard deviation (SD) of quadruplicates of a
representative experiment that was repeated at least three times.
FVB/neu mice tumour samples
For the in vivo analyses in mice, the FVB parental and FVB/N-
Tg (MMTVneu) 202 Mul/J strains (The Jackson Laboratory, Bar
Harbor, Maine) were manipulated at the animal facility (Servicio
de Experimentacio ´n Animal de la Universidad de Salamanca,
code: PAE/SA/001) following the European legal and institutional
guidelines (86/609/CEE). Tumour growth was evaluated after a
period of six months after birth, and tumour samples were
obtained after sacrifice of the animals, and immediately frozen in
liquid Nitrogen.
Western blotting experiments
Frozen human and mice tumoral samples were inspected by
haematoxylin-eosin staining for epithelial tumour content by
analysis of two slices at each end of the tumour. Only samples
containing .70% epithelial tumoral cells were selected for
Western analyses. The tumours were minced, washed with
phosphate-buffered saline (PBS), and homogenized in ice-cold
lysis buffer (140 mM NaCl; 10 mM EDTA; 10% glycerol; 2%
Triton X-100; 20 mM Tris pH 7.0; pepstatin, 10 mM; aprotinin,
10 mg/ml; leupeptin, 10 mg/ml; PMSF, 1 mM; beta-glycerophos-
phate, 25 mM; sodium fluoride, 10 mM; and sodium orthovana-
date, 10 mM) with a tight-fitting Dounce homogenizer [16]. This
homogenate was centrifuged at 10,0006g for 20 minutes at 4uC,
and the supernatants were transferred to new tubes. BT474 cell
extracts were prepared as described [14]. The samples (0.5 mg,
measured by the Bradford assay) were immunoprecipitated at 4uC
for at least 2 h with either the anti-Erk5 (1 ml) or the anti-pErk5
(10 ml) antibody and the immune complexes were recovered by a
short centrifugation, followed by three washes with 1 ml of cold
lysis buffer. Samples were then boiled in electrophoresis sample
buffer and loaded onto SDS-PAGE gels. After transfer to
polyvinylidene difluoride membranes, filters were blocked for
1 h in Tris buffered saline with 0.2% Tween 20 (TBST) and then
incubated for 2 to 16 h with the corresponding antibody. After
being washed with TBST, filters were incubated with horseradish
peroxidase-conjugated secondary antibodies for 30 min and bands
were visualized by a luminal-based detection system with p-
iodophenol enhancement [17].
Quantitation of Erk5, pErk5, HER2, pHER2 and pancytoker-
atins in Westerns was performed using the NIH Image 1.61
program. HER2 and pHER2 were analyzed as described [16].
The antibodies for calnexin or GAPDH, that we used as controls
for protein loading, were from Stressgen (Victoria, BC, Canada) or
Santa Cruz Biotechnology Inc (Santa Cruz, CA), respectively. The
anti-pancytokeratin antibody was from DakoCytomation (Carpin-
teria, CA).
Results
Expression of Erk5 in human breast cancer
Erk5 expression was analyzed by immunohistochemistry in
paraffin samples from 84 primary breast cancer tumours. For these
analyses, we used an affinity purified anti-Erk5 antibody that
recognizes the C-terminal region of Erk5 [14]. Using a two-tier
distribution (low/high) in which values equal to or above 2 were
considered positive (see Materials and Methods for details and
Figure 1A and B), high levels of Erk5 in the epithelial tumour cells
were observed in 17 patients (20% of the patients). We observed
two patterns of Erk5 staining. One corresponded to a diffuse
cytoplasmic signal (Figure 1C), and a second pattern was
represented by a perinuclear cytoplasmic accumulation of Erk5
(Figure 1D). Staining of Erk5 was also observed in the majority of
the endothelial cells and stromal fibroblasts. The staining of
endothelial cells may be related to the proposed role of Erk5 in
neoangiogenesis [11,12].
In addition to the study of overall Erk5 expression, we also
analyzed the degree of activation of Erk5. The mechanism of
activation of Erk5, as other MAPKs, involves dual phosphoryla-
tion of Erk5 at the Thr-Glu-Tyr microdomain that is present in its
activation loop (Figure 2A) [18]. Due to the lack of a specific
antibody that would only detect active Erk5 in immunohisto-
chemical analyses, we analyzed the level of active, dually
phosphorylated Erk5 by Western blotting. This activation can be
followed by either using an antibody that uniquely recognizes
double phosphorylated Erk5 (anti-pErk5), or by the anti-C-
terminus antibody described above that recognizes both Erk5
and pErk5 [14]. As pErk5 migrates slower than Erk5, both forms
can be differentiated in Western blotting experiments by their
different mobilities. Initially, we used two patient samples to
characterize the reaction of these antibodies on human tissue-
derived material; and used as a control BT474 cells which express
both Erk5 and pErk5 [14] (Figure 2B). The anti-Erk5 antibody
precipitated two Erk5 forms in the BT49 patient sample
(Figure 2B). When the BT49 immunoprecipitates were performed
in the presence of an excess of the peptide against which the anti-
Erk5 C-terminal antibody was raised, no Erk5 bands were
detected, indicating that in fact both bands corresponded to
Erk5. Analogously, the anti-pErk5 antibody specifically precipi-
tated the upper band in extracts from the BT1080 tumoral tissue,
indicating that this band corresponded to pErk5. The amount of
Erk5 and pErk5 was then analyzed on samples of patients from
which frozen tissue was available (n=23). Erk5 was detected in all
the samples; however, its amount varied among distinct patient
samples. In a substantial number of the samples analyzed a band
with a retarded migration with respect to Erk5, that corresponded
to pErk5, was observed (Figure 2C). We took these data to indicate
that Erk5 activation is frequent in breast cancer.
HER2 expression and Erk5 activation
As activation of Erk5 may be caused by activation of HER2
receptors in breast cancer in vitro [14], we analyzed whether such a
relationship also existed in vivo. To this end we used a mouse model
of breast cancer in which overexpression of HER2 provokes
mammary gland tumorigenesis [19]. Tumours resected from these
mice contained increased amounts of Erk5, pErk5, and HER2,
compared to normal breast tissue from the non-transgenic strain
(Figure 2D). The Erk5/pancytokeratin ratio present in the tumoral
tissue was higher than in normal breast, suggesting that in this
breast cancer model Erk5 was overexpressed in the epithelial
tumoral cells. Therefore, increased levels of HER2 may cause
increased expression of Erk5, and may favour its activation.
Immunohistochemical analyses of HER2 and Erk5 expression
in the patient series showed a trend towards a positive correlation
between high expression level of Erk5 and HER2 positivity
(p=0.074). Interestingly, in Western blot analysis from patients
samples, and even though in some tumours pErk5 accompanied
HER2 overexpression (e.gr. BT49), other tumours in which HER2
Erk5 in Human Breast Cancer
PLoS ONE | www.plosone.org 3 May 2009 | Volume 4 | Issue 5 | e5565was not overexpressed also contained pErk5 (e.gr. BT1304),
indicating that Erk5 may also be activated by routes other than
HER2 overexpression.
Association of Erk5 with prognosis
We reviewed the clinical characteristics of our series of patients
and studied if some of these characteristics such as age, tumour
grade, tumour size, hormone receptor status and axillary lymph
nodes, correlated with their amount of immunohistochemical
tumour Erk5. No correlation was observed for any of these
parameters, with the exception of a positive association with the
expression of the progesterone receptor (p=0.024) (Table 2).
To explore if Erk5 was associated with a more aggressive
phenotype, we studied the prognosis of these patients with respect
to the immunohistochemical Erk5 levels. Importantly, patients
with high levels of Erk5 (n=17) had a worse disease free survival
(DFS) time compared with the patients with low levels (n=67)
(log-rank test 10.20, p=0.0014) (Figure 3A). Median DFS time
was 34.33 (95% CI: 18.52–50.14) months for patients with low
Erk5 levels compared with 14.13 (95% CI: 3.78–24.48) months for
patients with high levels. An univariate analysis was performed to
study variables that could be associated with prognosis (Table 3).
In this analysis only oestrogen receptors, HER2 status by FISH,
and Erk5 were prognostic factors. A further multivariate analysis
using a Cox Regression model including the univariate prognostic
factors and those with clinical relevance in breast cancer, showed
that Erk5 was an independent prognostic factor (Table 4). The
influence of Erk5 on DFS was clearly demonstrated when HER2
positive and HER2 negative patients were analyzed separately
(Figure 3B and data not shown). Figure 3B shows the Kaplan-
Meier curve for HER2 positive patients regarding Erk5 expres-
sion. As can be seen, patients with Erk5 positive tumours have a
worse DFS compared with the negative ones. These findings
suggest that Erk5 may be a new biomarker associated with worse
outcome in breast cancer.
Erk5 regulates the response to anti-HER2 treatments
The negative impact of Erk5 overexpression on patient outcome
led us to analyze whether Erk5/pErk5 expression regulated the
response to treatments used in the breast cancer clinic. Since the
results obtained with the HER2 transgenic model together with
the analyses in patient samples indicated a relationship between
HER2 and Erk5/pErk5 levels, we investigated whether treatment
with agents that target HER2 had an effect on the levels or activity
of Erk5. BT474 cells, that express constitutively active HER2 and
Erk5 [14], were treated with the small molecule inhibitor of HER2
lapatinib, or trastuzumab. Treatment with lapatinib strongly
inhibited HER2 tyrosine phosphorylation, and decreased the level
Figure 1. Patterns of Erk5 staining in human breast cancer. Immunohistochemical staining of Erk5, showing samples scored as low (panel A),
or high expression level (panel B). Two patterns of Erk5 staining in breast cancer are shown in panels C and D. Magnification: for A and B, 2006; for C
and D, 10006.
doi:10.1371/journal.pone.0005565.g001
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pErk5 level, even though a small decrease was observed when
quantitative analyses were performed using the anti-Erk5 or anti-
pErk5 antibodies. Quantitative analyses of the pHER2/HER2
ratios indicated that trastuzumab had a very weak effect on HER2
activation. Concurrent cell proliferation studies indicated that
lapatinib reduced the proliferation of BT474 cells to a greater
extent than trastuzumab (Figure 4B).
The relative partial resistance to trastuzumab led us to
investigate whether decreasing Erk5 function could facilitate
trastuzumab action. We used two different strategies, one aimed
at decreasing Erk5 function by expressing a dominant negative
form; and another aimed at decreasing Erk5 levels using RNAi.
The dominant negative form of Erk5 (Erk5
AEF) acts by competing
with endogenous Erk5, impairing the activation of the latter [14].
Biochemical studies confirmed that BT474- Erk5
AEF expressed the
dominant negative form, and the RNAi strategy decreased Erk5/
pErk5 levels (Figure 4C). A three day treatment of BT474 cells
Figure 2. Molecular forms of Erk5 in human breast cancer. A, Schematic representation of Erk5 depicting the region where it is dually
phosphorylated at the TEY microdomain. B, Identification of the bands recognized by the anti-Erk5 antibodies in BT474 cells, and in the breast cancer
samples BT49, and BT1080. The immunoprecipitates and Westerns were probed with the indicated antibodies. Some samples were
immunoprecipitated with the antibodies but in the presence of an excess of the peptide used for the raising of the antibody, the peptide excess
prevented immunoprecipitation of both Erk5 bands. C, Molecular forms of Erk5 detected in breast cancer samples, and expression of HER2 and
pHER2. Calnexin was used as a control for protein loading. D, Expression of Erk5, pErk5, and HER2 in the breast of transgenic (FVB/neu) tumoral breast
tissue, or normal (FVB) breast tissue from mice. The amount of epithelial cytokeratins is shown.
doi:10.1371/journal.pone.0005565.g002
Table 2. Association between Clinicopathologic Variables
and Erk5 Expression.
Clinicopathologic variables p
Age 0.156*
Tumour grade 0.608*
Tumour size 0.201*
Estrogen Receptors 0.145 #
Progesterone Receptors 0.024 #{
Axillary lymph nodes 0.078 #
*Mann-Whitney U test.
#Fisher’s exact test.
{Statistically significant.
doi:10.1371/journal.pone.0005565.t002
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(mean6SD). In BT474-Erk5
AEF cells trastuzumab decreased
proliferation by 30.962.5%. In BT474 cells transfected with the
empty vector pSuper used for the RNAi experiments, trastuzumab
decreased their proliferation by 15.266.2%. In BT474 cells
transfected with the vector containing the Erk5 interference
sequence, trastuzumab decreased their proliferation by
27.766.3%. Therefore, treatments that decrease Erk5/pErk5
levels facilitate the antitumoral action of trastuzumab.
Discussion
This study was initiated on the basis of previous findings from
our group that showed a role of Erk5 in the control of breast
cancer cell proliferation [14]. In those studies, Erk5 was activated
by the HER ligand NRG, and interference with Erk5 activation
resulted in restricted cell proliferation [14]. Furthermore, in breast
cancer cells overexpressing HER2, Erk5 was constitutively
activated. Here we have studied Erk5 expression and relevance
in human breast cancer. Pathologic analyses indicated that Erk5
was overexpressed in 20% of patients with breast cancer.
Figure 3. Relationship between Erk5 expression and disease-free survival. A, Kaplan-Meier plots of disease-free survival with respect to
Erk5 levels in 84 early stage breast cancer patients. Patients with high levels of Erk5 (n=17) had a worse disease-free survival (DFS) time (14.13
months; 95% CI: 3.78–24.48) compared with patients (n=67) with low levels (34.33 months; 95% CI: 18.52–50.14). The difference was statistically
significant in the log-rank test (p=0.0014). B, Kaplan-Meier plots of disease-free survival with respect to Erk5 levels in 24 HER2 positive early stage
breast cancer patients. Patients with high levels of Erk5 (n=8) had a worse disease-free survival (DFS) time (9.70 months; 95% CI: 6.58–12.95)
compared to patients (n=16) with low levels (28 months; 95% CI: 15.53–41.40). The difference was statistically significant in the log-rank test
(p=0.012).
doi:10.1371/journal.pone.0005565.g003
Table 3. Association of Erk5 with Disease Free Survival in 84
Breast Cancer Patients Using the Univariate Proportional
Hazards Model (Cox Analisis).
Relative
risk 95% CI p
Erk5 Low expression vs. high 2.786 (1.389–5.587) 0.004
HER2 FISH amplification vs. no amplification 1.935 (1.011–3.704) 0.046
Tumour size ,3 vs. .3 cm 2.035 (0.967–4.280) 0.061
Axillary lymph nodes Positive vs. negative 1.821 (0.721–4.600) 0.205
Tumour Grade 1–2 vs. 3 1.663 (0.765–3.618) 0.199
Estrogen Receptors Positive vs. negative 0.421 (0.214–0.832) 0.013
Progesterone Receptors Positive
vs. negative
0.580 (0.285–1.180) 0.133
Age ,60 vs. .60 years 0.627 (0.309–1.274) 0.197
doi:10.1371/journal.pone.0005565.t003
Table 4. Prognostic Factors in 84 Breast Cancer Patients
Using the Backward Selection Model of the Cox Regression.
Relative
risk 95% CI p
Erk5 Low expression vs. high 3.799 (1.488–9.703) 0.005
HER2 FISH Amplification vs. no
amplification
1.364 (0.371–5.009) 0.640
Tumour size ,3 vs. .3 cm 2.141 (0.727–6.304) 0.167
Axillary lymph nodes Positive vs. negative 1.131 (0.275–4.651) 0.865
Tumour Grade 1–2 vs. 3 0.620 (0.155–2.480) 0.499
Estrogen Receptors Positive vs. negative 0.460 (0.120–1.177) 0.259
Progesterone Receptors Positive vs.
negative
1.894 (0.486–7.379) 0.358
Age ,60 vs. .60 years 0.650 (0.192–1.907) 0.391
doi:10.1371/journal.pone.0005565.t004
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cancer tumorigenesis in certain instances. Immunohistochemical
staining also showed expression of Erk5 in stromal tissue, as well as
in blood vessel endothelial cells. As Erk5 has been implicated in
tumour angiogenesis, its presence in the tumour vessels points to a
role of this kinase in the construction of the neovasculature of the
tumour, and may thus be considered a potential target for
therapeutic intervention.
As Erk5 has been shown to participate in proliferative signalling
upon activation of HER2 [14], we explored whether a correlation
existed between Erk5 expression levels or activation and HER2
expression in the patient series. With respect to the expression
levels, a trend was found between high level of expression of
immunohistochemical Erk5 and HER2 positivity. Furthermore,
tumours from mice in which overexpression of HER2 provokes
mammary gland tumorigenesis contained elevated levels of Erk5
when compared to normal tissue from non-transgenic animals.
These results indicate a certain degree of linkage between HER2
and Erk5 overexpression.
The frequent expression of pErk5 in breast tumours merits some
comments. Detectable levels of pErk5, as analyzed by Western
blotting experiments, were observed in most of the patient
samples. Given the precedents that link Erk5 activation to cell
proliferation [10], it is possible that expression of active Erk5 may
contribute tumour proliferation. One aspect that deserves
attention is the fact that our Western assays measured the pErk5
signal in the whole tumoral mass, which includes the epithelial as
well as the stromal tumoral tissue. It is therefore possible that a
fraction of the Erk5 and pErk5 signal may derive from the stromal
tumoral tissue. Noteworthy, we observed that the complement of
Erk5 in the stromal tumoral tissue as analyzed by immunohisto-
chemistry was variable between samples from different patients (e.
gr. Figure 1). This is important, and supports the increasingly
accepted concept that the stromal tissue that is part of the tumour
may phenotypically be distinct from the normal breast stroma.
With respect to the level of pErk5 and HER2, several evidences
indicate that activation of Erk5 may occur by HER2 overexpres-
sion but also through other mechanisms. In support of a linkage
Figure 4. Inhibition of Erk5 sensitizes to the action of Trastuzumab. A, Action of lapatinib and trastuzumab on Erk5, pErk5, and pHER2 in
BT474 cells. The drugs were added for 24 hours and then cell extracts prepared to be immunoprecipitated with anti-Erk5, anti-pErk5, or anti-HER2. B,
Effect of lapatinib (100 nM) or trastuzumab (10 nM) on the MTT uptake of BT474 cells. The results are reported as the mean6SD of quadruplicates. C,
Action of Erk5
AEF or Erk5 shRNA on cell proliferation. Erk5
AEF expression was measured by Western blot using an anti-HA tag antibody, as the Erk5
AEF
form is tagged with an HA epitope. GAPDH was used as a control for protein loading. BT474 cells transfected with the indicated vectors were treated
with trastuzumab and their proliferation measured using MTT uptake.
doi:10.1371/journal.pone.0005565.g004
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model we used, in which HER2-driven tumorigenesis is
accompanied by pErk5, and the fact that tumour patient samples
with HER2 overexpression and phospho-HER2 expression also
expressed pErk5. However, other patient samples presented pErk5
even though no overexpression of HER2 was detected. Indeed,
pErk5 was present more frequently than HER2 overexpression.
This is interesting as it indicates that Erk5/pErk5 levels may also
be regulated by HER2-independent routes. In support of this
conclusion is also the fact that treatment of BT474 cells with
lapatinib, that fully inhibited HER2 phosphorylation, only
partially inhibited pErk5 levels. Moreover, other membrane
receptors such as, IL6 receptor [20], or cytosolic kinases such as
Src [21], have also been reported to active Erk5.
A clinically relevant finding of our work is the linkage of Erk5
expression level to patient outcome. Thus, patients with high levels
of Erk5 relapsed earlier than patients with low Erk5. Statistically,
the expression level of this kinase was independent of other
prognostic factors, as was demonstrated by the multivariate
analyses. The predictive nature of Erk5 expression with respect
to disease relapse was also confirmed by using a selected set of
patients characterized by HER2 overexpresion. These findings
suggest that Erk5 may represent a potential interesting target.
Moreover, the fact, that in vitro reduction of Erk5 activation or
expression favoured the action of trastuzumab indicates that
targeting of Erk5 may facilitate the action of anti-HER2 therapies
and may also help in reverting drug resistance. With respect to the
latter, it will be interesting to define whether trastuzumab
resistance is accompanied by increased levels of Erk5 or pErk5.
In conclusion, our findings indicate that Erk5 may have an
important role in breast cancer, and its overexpression predicts
patient outcome. Furthermore, as Erk5 is expressed in tumoral as
well as other cellular components of the tumour, such as stromal
fibroblasts or endothelial cells, targeting of this kinase may be of
therapeutic benefit in breast cancer.
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